Viewing nowCombinationTobika Tablet 5/40 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Gunil Biopharm Co., Ltd.

MFDS item code 201903520 · Approved 2019.05.29 · Insurance code 073000030
Treatment of essential hypertension not controlled by monotherapy
Amlodipine or Olmesartan Medoxomil is used when blood pressure is not sufficiently controlled with monotherapy for patients with essential hypertension. These drugs work by dilating blood vessels to lower blood pressure and help reduce the risk of cardiovascular disease. They play an important role in effectively managing a patient's blood pressure to prevent complications. Therefore, they are actively used in the treatment of hypertension to improve blood pressure control.
Take one tablet once daily with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy with either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with olmesartan medoxomil 20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients in whom this medicine must not be administered, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
∘Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication or severe liver disease, severe aortic stenosis, bile duct obstruction, those on dialysis, patients in shock, and certain diabetic patients should not take this medication. When this drug is first administered to patients who are depleted of fluids or salt, hypotension may occur, so their condition should be closely monitored, and appropriate measures should be taken if hypotension develops. This drug has a vasodilating effect, and acute hypotension may occur in some patients, so caution is advised. Patients with severe heart disease should use caution as cardiac symptoms may worsen during the use of this medication. Patients with weakened kidney function or kidney disease should be cautious as this medication may further worsen kidney function. Patients with reduced liver function should take this medication with consideration of their liver function status since it is metabolized in the liver. During treatment, side effects like dizziness, headache, hypotension, swelling, digestive disturbances, and rash may occur; persistent symptoms should be discussed with healthcare professionals. This medication may interact with other medications, so patients should inform their healthcare providers of any other medications they are taking. In particular, taking this medication with grapefruit juice may enhance its effect, so it is recommended to avoid it. Women who are pregnant or breastfeeding should avoid taking this medication; if breastfeeding, they should consider whether to discontinue the medication or breastfeeding carefully. It is not recommended for children as safety and efficacy have not been established in pediatric patients under 18 years of age. Elderly patients may have reduced kidney and liver function, so treatment should start at a low dose with careful monitoring. In cases of overdose, symptoms such as hypotension or arrhythmia may occur, requiring immediate medical attention. This medication should be stored in a tightly sealed container to avoid exposure to light and moisture and kept out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to keep its efficacy and safety well preserved.
Pale yellow round film-coated tablet
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Gunil Biopharm Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.